New compound which eliminates antibiotic resistant organisms has been identified by scientists at the University of Sheffield and Rutherford Appleton Laboratory (RAL).
The team, led by Professor Jim Thomas, from the University of Sheffield's Department of Chemistry, is testing new compounds developed by his PhD student Kirsty Smitten on antibiotic resistant gram-negative bacteria, including pathogenic E. coli.
Drug Resistance - Antibiotic Resistance
Drug resistance is often a problem in malaria, tuberculosis, HIV, sexually transmitted diseases and hospital acquired diseases. Judicious use of antibiotics can control the problem.
Advertisement
‘New treatments for gram-negative bacteria are critical as they are rapidly becoming resistant to the existing drugs. This research could open the gate for new treatment of life-threatening superbugs and risk posed by the emergence of resistance.’
Read More..
Tweet it Now
Read More..
Gram-negative bacteria strains can cause infections including pneumonia, urinary tract infections and bloodstream infections. They are difficult to treat as the cell wall of the bacteria prevents drugs from getting into the microbe.
Antimicrobial resistance is already responsible for 25,000 deaths in the EU each year, and unless this rapidly emerging threat is addressed, it's estimated by 2050 more than 10 million people could die every year due to antibiotic resistant infections.
Doctors have not had a new treatment for gram-negative bacteria in the last 50 years, and no potential drugs have entered clinical trials since 2010.
The new drug compound has a range of exciting opportunities. As Professor Jim Thomas explains: "As the compound is luminescent it glows when exposed to light. This means the uptake and effect on bacteria can be followed by the advanced microscope techniques available at RAL.
"This breakthrough could lead to vital new treatments to life-threatening superbugs and the growing risk posed by antimicrobial resistance."
The studies at Sheffield and RAL have shown the compound seems to have several modes of action, making it more difficult for resistance to emerge in the bacteria. The next step of the research will be to test it against other multi-resistant bacteria.
In a recent report on antimicrobial resistant pathogens, the World Health Organisation put several gram-negative bacteria at the top of its list, stating that new treatments for these bacteria were 'Priority 1 Critical' because they cause infections with high death rates, are rapidly becoming resistant to all present treatments and are often picked up in hospitals.
The research, published in the journal ACS Nano, describes the new compound which kills gram-negative E. coli, including a multidrug resistant pathogen said to be responsible for millions of antibiotic resistant infections worldwide annually.
Source: Eurekalert
Advertisement
Doctors have not had a new treatment for gram-negative bacteria in the last 50 years, and no potential drugs have entered clinical trials since 2010.
The new drug compound has a range of exciting opportunities. As Professor Jim Thomas explains: "As the compound is luminescent it glows when exposed to light. This means the uptake and effect on bacteria can be followed by the advanced microscope techniques available at RAL.
"This breakthrough could lead to vital new treatments to life-threatening superbugs and the growing risk posed by antimicrobial resistance."
The studies at Sheffield and RAL have shown the compound seems to have several modes of action, making it more difficult for resistance to emerge in the bacteria. The next step of the research will be to test it against other multi-resistant bacteria.
In a recent report on antimicrobial resistant pathogens, the World Health Organisation put several gram-negative bacteria at the top of its list, stating that new treatments for these bacteria were 'Priority 1 Critical' because they cause infections with high death rates, are rapidly becoming resistant to all present treatments and are often picked up in hospitals.
The research, published in the journal ACS Nano, describes the new compound which kills gram-negative E. coli, including a multidrug resistant pathogen said to be responsible for millions of antibiotic resistant infections worldwide annually.
Source: Eurekalert
Advertisement
Advertisement
|
Advertisement
Latest Drug News
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial